Botulinum toxin in the treatment of OAB, BPH, and IC.
Botulinum neurotoxins (BoNTs) are well known for their ability to potently and selectively disrupt and modulate neurotransmission. BoNT is currently undergoing regulatory evaluation for urological disorders in the United States and the European Union and is not FDA approved for urologic use. Overactive bladder (OAB) and benign prostatic hyperplasia (BPH) are common urologic conditions characterized by urinary frequency, urgency, nocturia, urge incontinence and, in the case of BPH, decreased urine flow that are currently being evaluated in clinical trials with BoNT-A. Interstitial cystitis (IC) is a chronic condition in which patients describe urinary frequency, urgency and associated bladder/pelvic pain. In the two former conditions, BoNT-A is currently being evaluated in Phase II or Phase III clinical trials as a therapeutic agent. Evidence for BoNT in the treatment of IC is limited to small case series. The purpose of this article is to provide up to date clinical evidence regarding the use of BoNT to treat these three urologic problems. For the sake of clarity, BoNT-A describes the use of Botox unless otherwise specified. In addition, when describing OAB, two sub-populations exist: those with OAB of neurogenic origin (NDO) and those with OAB of unknown (idiopathic) origin (IDO).
Smith
Christopher P
CP
Scott Department of Urology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. cps@bcm.edu
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D018856:Cystitis, Interstitial / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009122:Muscle Hypertonia / Q000188:drug therapy; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A